Leukemia Research
Volume 28, Issue 3 , Pages 237-241, March 2004

The soluble form of CD83 is present at elevated levels in a number of hematological malignancies

  • Barry D Hock

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • Corresponding Author InformationCorresponding author. Tel.: +64-3-3640-579; fax: +64-3-3640-649.
    • ,
  • Lisa F Haring

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Alexander Steinkasserer

      Affiliations

    • Department of Dermatology, University Erlangen-Nuremberg, Erlangen, Germany
    • ,
  • Karen G Taylor

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • William N Patton

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Judith L McKenzie

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand

Received 5 March 2003; accepted 7 July 2003.

Abstract 

Recombinant forms of soluble CD83 (sCD83) inhibit anti-tumor responses. In this analysis of circulating sCD83 levels we report that although >95% of acute myeloid leukemia (AML) and multiple myeloma (MM) patients have normal or only weakly elevated sCD83 levels, 20% of chronic lymphocytic leukemia (CLL) and 5/7 mantle cell lymphoma (MCL) patients have significantly elevated levels (>1ng/ml). Isolated CLL cells both weakly expressed membrane CD83 (mCD83), and released sCD83 during in vitro culture. We conclude that malignant cells are a potential source of sCD83 and that it may have functional and/or prognostic significance in hematological malignancies, particularly CLL and MCL.

Keywords:  Soluble CD83, Leukemia, Non-Hodgkin’s lymphoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(03)00255-8

doi:10.1016/S0145-2126(03)00255-8

Leukemia Research
Volume 28, Issue 3 , Pages 237-241, March 2004

Article Tools

* Image Usage & Resolution